Stock Track | Alvotech Plunges 8.39% in Pre-market Following Q3 Miss and Ongoing Challenges

Stock Track11-13

Shares of Alvotech (NASDAQ: ALVO) continued their downward trajectory, plummeting 8.39% in pre-market trading on Thursday. This sharp decline follows a 7.68% drop during Wednesday's regular trading session, as investors reacted to the company's disappointing third-quarter earnings report and reduced full-year guidance.

The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million. More concerning for investors, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million, further dampening market sentiment.

Adding to the pressure on Alvotech's stock are ongoing regulatory concerns stemming from an FDA inspection of its Reykjavik facility in July. While the company emphasized that resolving these issues is a "top priority," the unresolved status continues to weigh on investor confidence. Furthermore, Alvotech's cash position decreased to $42.8 million as of September 30, driven by inventory build-up, capital expenditures, and recent acquisitions. Despite securing a new $100 million working capital option, the cash burn rate remains a significant concern for investors, contributing to the continued sell-off in the pre-market session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199474991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199474991","market":"sg","top_or_hot":-1,"title":"Stock Track | Alvotech Plunges 8.39% in Pre-market Following Q3 Miss and Ongoing Challenges","media":"Stock Track","content":"<p>Shares of Alvotech (NASDAQ: ALVO) continued their downward trajectory, plummeting 8.39% in pre-market trading on Thursday. This sharp decline follows a 7.68% drop during Wednesday's regular trading session, as investors reacted to the company's disappointing third-quarter earnings report and reduced full-year guidance.</p>\n\n<p>The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million. More concerning for investors, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million, further dampening market sentiment.</p>\n\n<p>Adding to the pressure on Alvotech's stock are ongoing regulatory concerns stemming from an FDA inspection of its Reykjavik facility in July. While the company emphasized that resolving these issues is a \"top priority,\" the unresolved status continues to weigh on investor confidence. Furthermore, Alvotech's cash position decreased to $42.8 million as of September 30, driven by inventory build-up, capital expenditures, and recent acquisitions. Despite securing a new $100 million working capital option, the cash burn rate remains a significant concern for investors, contributing to the continued sell-off in the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alvotech Plunges 8.39% in Pre-market Following Q3 Miss and Ongoing Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alvotech Plunges 8.39% in Pre-market Following Q3 Miss and Ongoing Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Alvotech (NASDAQ: ALVO) continued their downward trajectory, plummeting 8.39% in pre-market trading on Thursday. This sharp decline follows a 7.68% drop during Wednesday's regular trading session, as investors reacted to the company's disappointing third-quarter earnings report and reduced full-year guidance.</p>\n\n<p>The Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million. More concerning for investors, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million, further dampening market sentiment.</p>\n\n<p>Adding to the pressure on Alvotech's stock are ongoing regulatory concerns stemming from an FDA inspection of its Reykjavik facility in July. While the company emphasized that resolving these issues is a \"top priority,\" the unresolved status continues to weigh on investor confidence. Furthermore, Alvotech's cash position decreased to $42.8 million as of September 30, driven by inventory build-up, capital expenditures, and recent acquisitions. Despite securing a new $100 million working capital option, the cash burn rate remains a significant concern for investors, contributing to the continued sell-off in the pre-market session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALVO","symbol_name":"Alvotech","start_time":0,"source_url":"","article_id":"1199474991","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199474991","pubTimestamp":1763032220,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Alvotech (NASDAQ: ALVO) continued their downward trajectory, plummeting 8.39% in pre-market trading on Thursday. This sharp decline follows a 7.68% drop during Wednesday's regular trading...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALVO":"Alvotech"},"translate_title":"股票追踪|Alvotech在第三季度表现不佳和持续挑战后盘前暴跌8.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVO":1},"content_text":"Shares of Alvotech (NASDAQ: ALVO) continued their downward trajectory, plummeting 8.39% in pre-market trading on Thursday. This sharp decline follows a 7.68% drop during Wednesday's regular trading session, as investors reacted to the company's disappointing third-quarter earnings report and reduced full-year guidance.\nThe Iceland-based biosimilars developer reported Q3 revenue of $113.744 million, falling short of analyst expectations of $117.203 million. More concerning for investors, Alvotech lowered its full-year 2025 revenue guidance to $570-$600 million, down from previous estimates. The company also reduced its adjusted EBITDA forecast to $130-$150 million, further dampening market sentiment.\nAdding to the pressure on Alvotech's stock are ongoing regulatory concerns stemming from an FDA inspection of its Reykjavik facility in July. While the company emphasized that resolving these issues is a \"top priority,\" the unresolved status continues to weigh on investor confidence. Furthermore, Alvotech's cash position decreased to $42.8 million as of September 30, driven by inventory build-up, capital expenditures, and recent acquisitions. Despite securing a new $100 million working capital option, the cash burn rate remains a significant concern for investors, contributing to the continued sell-off in the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199474991","isCrawlerRequest":true}